Deutsche Bank AG Sells 742,739 Shares of GSK plc (NYSE:GSK)

Deutsche Bank AG lowered its position in shares of GSK plc (NYSE:GSK - Free Report) by 99.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,676 shares of the pharmaceutical company's stock after selling 742,739 shares during the quarter. Deutsche Bank AG's holdings in GSK were worth $260,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Crestline Management LP bought a new stake in GSK in the fourth quarter valued at about $1,047,000. Bridgefront Capital LLC grew its stake in GSK by 73.1% in the fourth quarter. Bridgefront Capital LLC now owns 16,665 shares of the pharmaceutical company's stock valued at $564,000 after acquiring an additional 7,037 shares during the period. Cary Street Partners Financial LLC acquired a new position in GSK in the fourth quarter valued at about $228,000. Bayesian Capital Management LP acquired a new position in GSK in the fourth quarter valued at about $475,000. Finally, Beverly Hills Private Wealth LLC grew its stake in GSK by 94.6% in the fourth quarter. Beverly Hills Private Wealth LLC now owns 29,397 shares of the pharmaceutical company's stock valued at $994,000 after acquiring an additional 14,288 shares during the period. Institutional investors own 15.74% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GSK. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. BNP Paribas began coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective for the company. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. Finally, Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have issued a strong buy rating to the stock. According to MarketBeat, GSK currently has a consensus rating of "Hold" and an average target price of $37.38.

GSK Trading Up 0.8%

GSK traded up $0.31 during midday trading on Thursday, hitting $41.11. 3,247,422 shares of the company were exchanged, compared to its average volume of 4,820,645. The firm's 50 day moving average price is $37.48 and its 200-day moving average price is $36.28. GSK plc has a 1-year low of $31.72 and a 1-year high of $44.67. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market capitalization of $84.82 billion, a P/E ratio of 25.86, a P/E/G ratio of 1.12 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same period last year, the company posted $0.43 EPS. The business's quarterly revenue was up 2.1% on a year-over-year basis. As a group, equities analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.10%. GSK's dividend payout ratio (DPR) is 86.60%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.